Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 3/2016

01-07-2016 | Erratum

Erratum to: Vegfr3-CreER T2 mouse, a new genetic tool for targeting the lymphatic system

Authors: Ines Martinez-Corral, Lukas Stanczuk, Maike Frye, Maria Helena Ulvmar, Rodrigo Diéguez-Hurtado, David Olmeda, Taija Makinen, Sagrario Ortega

Published in: Angiogenesis | Issue 3/2016

Login to get access

Excerpt

In the original publication of the article, the last name of one of the co-authors has been published incorrectly. The correct name is Rodrigo Diéguez-Hurtado. …
Metadata
Title
Erratum to: Vegfr3-CreER T2 mouse, a new genetic tool for targeting the lymphatic system
Authors
Ines Martinez-Corral
Lukas Stanczuk
Maike Frye
Maria Helena Ulvmar
Rodrigo Diéguez-Hurtado
David Olmeda
Taija Makinen
Sagrario Ortega
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 3/2016
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-016-9518-5

Other articles of this Issue 3/2016

Angiogenesis 3/2016 Go to the issue

Original Paper

Association of endothelial proliferation with the magnitude of weight loss during calorie restriction

Brief Communication

Vegfr3-CreER T2 mouse, a new genetic tool for targeting the lymphatic system

Original Paper

Aflibercept exhibits VEGF binding stoichiometry distinct from bevacizumab and does not support formation of immune-like complexes

Original Paper

CD34 expression modulates tube-forming capacity and barrier properties of peripheral blood-derived endothelial colony-forming cells (ECFCs)

Original Paper

Circulating angiopoietin-2 levels in children and adolescents with type 1 diabetes mellitus: relation to carotid and aortic intima-media thickness

Review Paper

HIF inhibitors for ischemic retinopathies and cancers: options beyond anti-VEGF therapies
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits